.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Unraveling The Key Questions in EGFR-Driven NSCLC Treatment

Heather Wakelee, MD, FASCO, and Roy S. Herbst, MD, PhD, discuss how recent clinical trials demonstrate superior outcomes with combination therapies over single-agent osimertinib in EGFR-positive NSCLC, while highlighting the need for careful toxicity management and continued research to address treatment resistance.

EP. 1: EGFR mNSCLC: Treatment Overview and Challenges

February 13th 2025

Panelists discuss how EGFR tyrosine kinase inhibitors (TKIs) have revolutionized first-line treatment for EGFR-positive non–small cell lung cancer (NSCLC).

EP. 2: FLAURA and FLAURA2: Key Efficacy and Safety Data

February 20th 2025

Panelists discuss how osimertinib monotherapy demonstrated robust progression-free survival and overall survival benefits in FLAURA, while FLAURA2 showed that adding chemotherapy to osimertinib further improved progression-free survival (PFS) although overall survival (OS) data remains immature, leading to ongoing debate about the optimal first-line approach.